BLASUBCUTANEOUSINJECTABLE4 Generics Approved
Approved
Mar 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
JUBBONTI (denosumab) by Novartis is rank ligand blocking activity [moa]. Approved for rank ligand inhibitor [epc]. First approved in 2024.
Drug data last refreshed 17h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JUBBONTI (denosumab) is a monoclonal antibody that blocks RANK ligand, a key driver of bone resorption and immune cell activation. It is administered subcutaneously and treats conditions characterized by elevated bone turnover, including osteoporosis and bone metastases. The drug works by inhibiting osteoclast formation and survival, reducing bone loss and fracture risk.
Growth
Early-stage growth product with moderate competitive pressure (30%) entering an established market dominated by Amgen's legacy franchise; commercial team expansion likely as market penetration accelerates.
Mechanism of Action
RANK Ligand Blocking Activity
Pharmacologic Class:
RANK Ligand Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Study on the Intervention Effect of Denosumab on High-Risk Patients With Osteoporotic Fractures in Type 2 Diabetes
Started Feb 2026
358 enrolled
Type 2 DiabetesOsteoporosisFractures
A Clinical Study Evaluating the Dermal Safety of Soluble Denosumab Microneedle Patches
Started Jul 2025
12 enrolled
OsteoarthritisOsteoarthritis (OA) of the KneeOsteoporosis+2 more
Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease
Started Apr 2024
478 enrolled
Multiple MyelomaBone Diseases
Clinical Controlled Study on the Efficacy of Denosumab in Treating Osteoporosis in the Domestic Population and Its Impact on Sarcopenia-related Outcomes
Started Feb 2024
86 enrolled
SarcopeniaOsteoporosisDenosumab
Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)
Started Nov 2023
122 enrolled
Osteoporosis, Postmenopausal
Worked on JUBBONTI at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.